Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 region II malaria vaccine in healthy adults living in an area where malaria is not endemic

Clinical and Vaccine Immunology

Volumn 17, Issue 10, 2010, Pages 1552-1559

  El Sahly, H M ^a   Patel, S M ^a   Atmar, R L ^a   Lanford, T A ^a   Dube, T ^c   Thompson, D ^c   Sim, B K L ^d   Long, C ^b   Keitel, W A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c EMMES CORPORATION   (United States)

^d Protein Potential LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM PHOSPHATE; MALARIA VACCINE; PLACEBO; RECOMBINANT ERYTHROCYTE BINDING ANTIGEN 175; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EDEMA; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MALAISE; MALARIA; MALE; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUMINUM COMPOUNDS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN EXPERIMENTATION; HUMANS; IMMUNIZATION, SECONDARY; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PHOSPHATES; PLACEBOS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; UNITED STATES; VACCINATION; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 77957872219     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00082-10     Document Type: Article

References (42)

1. Adams, J. H., B. K. Sim, S. A. Dolan, X. Fang, D. C. Kaslow, and L. H. Miller. 1992. A family of erythrocyte binding proteins of malaria parasites. Proc. Natl. Acad. Sci. U. S. A. 89:7085-7089.
2. Baum, J., M. Pinder, and D. J. Conaway. 2003. Erythrocyte invasion phenotypes of Plasmodium falciparum in The Gambia. Infect. Immun. 71:1856-1863.
3. Baum, J., A. W. Thomas, and D. J. Conway. 2003. Evidence for diversifying selection on erythrocyte-binding antigens of Plasmodium falciparum and P. vivax. Genetics 163:1327-1336.
4. Bejon, P., J. Lusingo, A. Olotu, A. Leach, M. Lievens, J. Vekemans, S. Mshamu, T. Lang, J. Gould, M. C. Dubois, M. A. Demoitié, J. F. Stallaert, P. Vansadia, T. Carter, P. Njuguna, K. O. Awuondo, A. Malabeja, O. Abdul, S. Gesase, N. Mturi, C. J. Drakely, B. Savarese, T. Villafana, W. R. Ballou, J. Cohen, E. M. Riley, M. M. Lemnge, K. Marsh, and L. von Seidlein. 2008. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359:2521-2532.
5. Bhattarai, A., A. S. Ali, S. P. Kachur, A. Mårtensson, A. K. A. K. Abbas, R. Khatib, A. W. Al-Mafazy, M. Ramsan, G. Rotllant, J. F. Gerstenmaier, F. Molteni, S. Abdulla, S. M. Montgomery, A. Kaneko, and A. Björkman. 2007. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 4:e309. (Pubitemid 350220531)
6. Bruder, J. T., M. E. Stefaniak, N. B. Patterson, P. Chen, S. Konovalova, K. Limbach, J. J. Campo, D. Ettyreddy, S. Li, F. Dubovsky, T. L. Richie, C. R. King, C. A. Long, and D. L. Doolan. 2010. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine 28:3201-3210.
7. Camus, D., and T. J. Hadley. 1985. A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Science 230:553-556.
8. Ceesay, S. J., C. Casals-Pascual, J. Erskine, S. E. Anya, N. O. Duah, A. J. Fulford, S. S. Sesay, I. Abubakar, S. Dunyo, O. Sey, A. Palmer, M. Fofana, T. Corrah, K. A. Bojang, W. C. Whittle, B. M. Greenwood, and D. J. Conway. 2008. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet 372:1545-1554.
9. Crompton, P. D., K. Miura, B. Traore, K. Kayentao, A. Ongoiba, G. Weiss, S. Doumbo, D. Doumtabe, Y. Kone, C. Y. Huang, O. K. Doumbo, L. H. Miller, C. A. Long, and S. K. Pierce. 2010. In vitro growth-inhibitory activity and malaria risk in a cohort study in Mali. Infect. Immun. 78:737-745.
10. Dicko, A., D. J. Diemert, I. Sagara, M. Sogoba, M. B. Niambele, M. H. Assadou, O. Guindo, B. Kamate, M. Baby, M. Sissoko, E. M. Malkin, M. P. Fay, M. A. Thera, K. Miura, A. Dolo, D. A. Diallo, G. E. Mullen, C. A. Long, A. Saul, O. Doumbo, and L. H. Miller. 2007. Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS One 2:e1045.
11. Druilhe, P., F. Spertini, D. Soesoe, G. Corradin, P. Mejia, S. Singh, R. Audran, A. Bouzizi, C. Oeuvray, and C. Roussilhon. 2005. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2:e344.
12. Ellis, R. D., L. B. Martin, D. Shaffer, C. A. Long, K. Miura, M. P. Fay, D. L. Narum, D. Zhu, G. E. Mullen, S. Mahanty, L. H. Miller, and A. P. Durbin. 2010. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults. PLoS One 5:e8787.
13. Fegan, G. W., A. M. Noor, W. S. Akhwale, S. Cousens, and R. W. Snow. 2007. Effect of expanded insecticide-treated bednet coverage on child survival in rural Kenya: a longitudinal study. Lancet 370:1035-1039.
14. Gaur, D., S. Singh, S. Singh, L. Jiang, A. Diouf, and L. H. Miller. 2007. Recombinant Plasmodium falciparum reticulocyte homology protein 4 binds to erythrocytes and blocks invasion. Proc. Natl. Acad. Sci. U. S. A. 104: 17789-17794.
15. Genton, B., I. Betuela, I. Felger, F. Al-Yaman, R. F. Anders, A. Saul, L. Rare, M. Baisor, K. Lorry, G. V. Brown, D. Pye, D. O. Irving, T. A. Smith, H. P. Beck, and M. P. Alpers. 2002. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185:820-827.
16. Hoffman, S. L., L. M. Goh, T. C. Luke, I. Schneider, T. P. Le, D. L. Doolan, J. Sacci, P. de la Vega, M. Dowler, C. Paul, D. M. Gordon, J. A. Stoute, L. W. Church, M. Sedegah, D. G. Heppner, W. R. Ballou, and T. L. Richie. 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185:1155-1164.
17. Jones, T. R., D. L. Narum, A. S. Gozalo, J. Aguiar, S. R. Fuhrmann, H. Liang, J. D. Haynes, J. K. Moch, C. Lucas, T. Luu, A. J. Magill, S. L. Hoffman, and B. K. Sim. 2001. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J. Infect. Dis. 183:303-312.
18. Keitel, W. A., K. E. Kester, R. L. Atmar, A. C. White, N. H. Bond, C. A. Holland, U. Krzych, D. R. Palmer, A. Egan, C. Diggs, W. R. Ballou, B. F. Hall, and D. Kaslow. 1999. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 18:531-539.
19. Liang, H., and B. K. Sim. 1997. Conservation of structure and function of the erythrocyte-binding domain of Plasmodium falciparum EBA-175. Mol. Biochem. Parasitol. 84:241-245.
20. Malkin, E. M., D. J. Diemert, J. H. McArthur, J. R. Perreault, A. P. Miles, B. K. Giersing, G. E. Mullen, A. Orcutt, O. Muratova, M. Awkal, H. Zhou, J. Wang, A. Stowers, C. A. Long, S. Mahanty, L. E. Miller, S. A. Saul, and A. P. Durbin. 2005. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect. Immun. 73:3677-3685.
21. Miura, K., A. C. Orcutt, O. V. Muratova, L. H. Miller, A. Saul, and C. A. Long. 2008. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26:193-200.
22. Miura, K., H. Zhou, S. Moretz, A. Diouf, D. Diemert, M. A. Thera, A. Dolo, O. Doumbo, E. Malkin, D. Diemert, L. H. Miller, G. E. Mullen, and C. A. Long. 2008. Comparison of biological activity of human anti-apical membrane antigen 1 antibodies induced by infection and vaccination. J. Immunol. 181:8776-8783.
23. Nardin, E. H., G. A. Oliveira, J. M. Calvo-Calle, Z. R. Castro, R. S. Nussenzweig, B. Schmeckpeper, B. F. Hall, C. Diggs, S. Bodison, and R. Edelman. 2000. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J. Infect. Dis. 182:1486-1496.
24. Narum, D. L., J. D. Haynes, S. Fuhrmann, K. Moch, H. Liang, S. L. Hoffman, and B. K. Sim. 2000. Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect. Immun. 68:1964-1966.
25. O'Donnell, R. A., T. F. de Koning-Ward, R. A. Burt, M. Bockarie, J. C. Reeder, A. F. Cowman, and B. S. Crabb. 2001. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J. Exp. Med. 193:1403-1412.
26. Oeuvray, C., M. Theisen, C. Rogier, J. F. Trape, S. Jepsen, and P. Druilhe. 2000. Cytophilic immunoglobulin responses to Plasmodium falciparum glu- tamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect. Immun. 68:2617-2620.
27. Ohas, E. A., J. H. Adams, J. N. Waitumbi, A. S. Orago, A. Barbosa, D. E. Lanar, and J. A. Stoute. 2004. Measurement of antibody levels against region II of the erythrocyte-binding antigen 175 of Plasmodium falciparum in an area of malaria holoendemicity in western Kenya. Infect. Immun. 72:735-741.
28. Okenu, D. M., E. M. Riley, Q. D. Bickle, P. U. Agomo, A. Barbosa, J. R. Daugherty, D. E. Lanar, and D. J. Conway. 2000. Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum. Infect. Immun. 68:5559-5566.
29. Okoyeh, J. N., C. R. Pillai, and C. E. Chitnis. 1999. Plasmodium falciparum field isolates commonly use erythrocyte invasion pathways that are independent of sialic acid residues of glycophorin A. Infect. Immun. 67:5784-5791.
30. Pandey, K. C., S. Singh, P. Pattnaik, C. R. Pillai, U. Pillai, A. Lynn, S. K. Jain, and C. E. Chitnis. 2002. Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. Mol. Biochem. Parasitol. 123:23-33.
31. Peek, L. J., D. T. Brandau, L. S. Jones, S. B. Joshi, and C. R. Middaugh. 2006. A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. Vaccine 24:5839-5851.
32. Perraut, R., L. Marrama, B. Diouf, C. Sokhna, A. Tall, P. Nabeth, J. F. Trape, S. Longacre, and O. Mercerau-Puijalon. 2005. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J. Infect. Dis. 191:264-271.
33. Pombo, D. J., G. Lawrence, C. Hirunpetcharat, C. Rzepczyk, M. Bryden, N. Cloonan, K. Anderson, Y. Mahakunkijcharoen, L. B. Martin, D. Wilson, S. Elliott, S. Elliott, D. P. Eisen, J. B. Weinberg, A. Saul, and M. F. Good. 2002. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360:610-617.
34. Richie, T. 2006. High road, low road? Choices and challenges on the pathway to a malaria vaccine. Parasitology 133(Suppl.):S113-S144.
35. Saul, A. 2007. Mosquito stage, transmission blocking vaccines for malaria. Curr. Opin. Infect. Dis. 20:476-481.
36. Schofield, L., M. C. Hewitt, K. Evans, M. A. Siomos, and P. H. Seeberger. 2002. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 418:785-789.
37. Sim, B. K., C. E. Chitnis, K. Wasniowska, T. J. Hadley, and L. H. Miller. 1994. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 264:1941-1944.
38. Sim, B. K., D. L. Narum, L. H. Liang, S. R. Fuhrmann, N. Obaldia III, R. Gramzinski, J. Aguiar, J. D. Haynes, J. K. Moch, and S. L. Hoffman. 2001. Induction of biologically active antibodies in mice, rabbits, and monkeys by Plasmodium falciparum EBA-175 region II DNA vaccine. Mol. Med. 7:247-254.
39. Sim, B. K., P. A. Orlandi, J. D. Haynes, F. W. Klotz, J. M. Carter, D. Camus, M. E. Zegans, and J. D. Chulay. 1990. Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J. Cell Biol. 111:1877-1884.
40. van Dijk, M. R., B. Douradinha, B. Franke-Fayard, V. Heussler, M. W. van Dooren, B. van Shaijk, G. J. van Gemert, R. W. Sauerwein, M. M. Mota, A. P. Waters, and C. J. Janse. 2005. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc. Natl. Acad. Sci. U. S. A. 102:12194-12199.
41. WHO. 2008. World malaria report. WHO, Geneva, Switzerland. http://www .who.int/malaria/wmr2008/malaria2008.pdf.
42. Zhang, D., and W. Pan. 2005. Evaluation of three Pichia pastoris-expressed Plasmodium falciparum merozoite proteins as a combination vaccine against infection with blood-stage parasites. Infect. Immun. 73:6530-6536.